- Oxford Biodynamics
- 09 May 2025 13:06:17
Source: Sharecast
The AIM-traded company said it had also completed clinical validation of its EpiSwitch Checkpoint Inhibitor Response Test (CiRT) within the UK lab, which would improve turnaround times for test results.
Previously, CiRT testing for UK patients was carried out at the company’s CLIA-certified facility in the US.
With the accreditation, all orders for CiRT and its prostate screening test (PSE) in the UK and Europe would now be processed domestically.
Oxford BioDynamics said the development was a significant step in expanding its precision diagnostics offering, and enhancing service delivery for clinicians across the region.
“The immediate benefit for cancer patients seeking a CiRT test in the UK will be the significant reduction in the elapsed time from receipt of an order to result, which will now be three to five days,” said chief operating officer Thomas Guiel.
“UKAS accreditation of our clinical lab in the UK under ISO15189 is a significant milestone that underscores our dedication to delivering high-quality and timely diagnostic testing to support healthcare providers and patients in the UK and Europe, meeting the stringent ISO requirements for patient testing and data security.”
At 1235 BST, shares in Oxford BioDynamics were up 3.36% at 0.4p.
Reporting by Josh White for Sharecast.com.
